(FRE) Fresenius SE & Co. KGaA - Ratings and Ratios

Fresenius SE & Co. KGaA is a diversified healthcare conglomerate providing a range of products and services for chronically ill patients across various business segments. The companys operations are segmented into Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed, each catering to different aspects of healthcare, from dialysis and nutrition products to clinical care facilities and healthcare facility management.

The companys business segments are positioned in growing markets: Fresenius Medical Care is a leading provider of dialysis products and services, Fresenius Kabi specializes in infusion and nutrition therapies, Fresenius Helios is one of Europes largest hospital operators, and Fresenius Vamed provides a range of services for healthcare facilities. This diversification provides a robust foundation for the companys growth and stability.

From a technical analysis perspective, the stock has shown a positive trend, with its last price at €43.49, above its 20-day, 50-day, and 200-day Simple Moving Averages (SMA) of €42.42, €40.06, and €35.61, respectively. The Average True Range (ATR) indicates a moderate volatility of 1.83%. Given the current technical setup, a potential forecast could be that the stock continues its upward trend, potentially reaching towards its 52-week high of €44.03, provided it can maintain its current momentum.

Fundamentally, Fresenius has a market capitalization of €24.8 billion and a P/E ratio of 23.55, which is somewhat high but expected to decrease to 12.69 in the forward P/E, indicating potential for earnings growth. The Return on Equity (RoE) is 2.20%, a figure that could be improved through operational efficiencies and strategic acquisitions. By combining fundamental and technical analysis, a forecast could be made that Fresenius is poised for growth, driven by its diversified healthcare portfolio, improving earnings, and a positive technical trend, potentially reaching a price target above €45 in the near term, contingent on maintaining its current growth trajectory and improving its operational metrics.